Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Cancer pharmacoinformatics: Databases and analytical tools

Cancer is a subject of extensive investigation, and the utilization of omics technology has resulted in the generation of substantial volumes of big data in cancer research. Numerous databases are being developed to manage and organize this data effectively. These databases encompass various domains such as genomics, transcriptomics, proteomics, metabolomics, immunology, and drug discovery. The application of computational tools into various core components of pharmaceutical sciences constitutes "Pharmacoinformatics", an emerging paradigm in rational drug discovery. The three major features of pharmacoinformatics include (i) Structure modelling of putative drugs and targets, (ii) Compilation of databases and analysis using statistical approaches, and (iii) Employing artificial intelligence/machine learning algorithms for the discovery of novel therapeutic molecules. The development, updating, and analysis of databases using statistical approaches play a pivotal role in pharmacoinformatics. Multiple software tools are associated with oncoinformatics research. This review catalogs the databases and computational tools related to cancer drug discovery and highlights their potential implications in the pharmacoinformatics of cancer.

MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations

Combination therapy is a promising strategy for the successful treatment of cancer. The large number of possible combinations, however, mean that it is laborious and expensive to screen for synergistic drug combinations in vitro. Nevertheless, because of the availability of high-throughput screening data and advances in computational techniques, deep learning (DL) can be a useful tool for the prediction of synergistic drug combinations. In this study, we proposed a multimodal DL framework, MMSyn, for the prediction of synergistic drug combinations. First, features embedded in the drug molecules were extracted: structure, fingerprint, and string encoding. Then, gene expression data, DNA copy number, and pathway activity were used to describe cancer cell lines. Finally, these processed features were integrated using an attention mechanism and an interaction module and then input into a multilayer perceptron to predict drug synergy. Experimental results showed that our method outperformed five state-of-the-art DL methods and three traditional machine learning models for drug combination prediction. We verified that MMSyn achieved superior performance in stratified cross-validation settings using both the drug combination and cell line data. Moreover, we performed a set of ablation experiments to illustrate the effectiveness of each component and the efficacy of our model. In addition, our visual representation and case studies further confirmed the effectiveness of our model. All results showed that MMSyn can be used as a powerful tool for the prediction of synergistic drug combinations.

Up to the Herculean Task of Tackling Cancer Therapy Resistance

Cancer therapy resistance still poses the biggest hurdle to cancer treatment [...].

Response score-based protein structure analysis for cancer prediction aided by the Internet of Things

Medical diagnosis through prediction and analysis is par excellence in integrating modern technologies such as the Internet of Things (IoT). With the aid of such technologies, clinical assessments are eased with protracted computing. Specifically, cancer research through structure prediction and analysis is improved through human and machine interventions sustaining precision improvements. This article, therefore, introduces a Protein Structure Prediction Technique based on Three-Dimensional Sequence. This sequence is modeled using amino acids and their folds observed during the pre-initial cancer stages. The observed sequences and the inflammatory response score of the structure are used to predict the impact of cancer. In this process, ensemble learning is used to identify sequence and folding responses to improve inflammations. This score is correlated with the clinical data for structures and their folds independently for determining the structure changes. Such changes through different sequences are handled using repeated ensemble learning for matching and unmatching response scores. The introduced idea integrated with deep ensemble learning and IoT combination, notably employing stacking method for enhanced cancer prediction precision and interdisciplinary collaboration. The proposed technique improves prediction precision, data correlation, and change detection by 11.83%, 8.48%, and 13.23%, respectively. This technique reduces correlation time and complexity by 10.43% and 12.33%, respectively.